MA33607B1 - Molécules de liaison bispécifiques pour une thérapie anti-angiogénique - Google Patents

Molécules de liaison bispécifiques pour une thérapie anti-angiogénique

Info

Publication number
MA33607B1
MA33607B1 MA34720A MA34720A MA33607B1 MA 33607 B1 MA33607 B1 MA 33607B1 MA 34720 A MA34720 A MA 34720A MA 34720 A MA34720 A MA 34720A MA 33607 B1 MA33607 B1 MA 33607B1
Authority
MA
Morocco
Prior art keywords
binding molecules
bispecific binding
relates
angiogenic therapy
dll4
Prior art date
Application number
MA34720A
Other languages
Arabic (ar)
English (en)
Inventor
Eric Borges
Andreas Gschwind
Joachim Boucneau
Tavernier Evelyn De
Joost Kolkman
Pascal Merchiers
Hoorick Diane Van
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33607(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33607B1 publication Critical patent/MA33607B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne des molécules de liaison bispécifiques, en particulier des domaines variables uniques d'immunoglobuline tels que des vhh et des anticorps à domaine comprenant un composant de liaison à vegf et un composant de liaison à dll4 dans une molécule. L'invention concerne également des compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies qui sont associées à des effets à médiation par vegf et dll4 sur l'angiogenèse. L'invention concerne également des acides nucléiques codant pour les molécules de liaison bispécifiques, des cellules hôtes et des procédés pour les préparer.
MA34720A 2009-10-02 2012-03-26 Molécules de liaison bispécifiques pour une thérapie anti-angiogénique MA33607B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172137 2009-10-02
EP10175316 2010-09-03
PCT/EP2010/064695 WO2011039370A1 (fr) 2009-10-02 2010-10-01 Molécules de liaison bispécifiques pour une thérapie anti-angiogénique

Publications (1)

Publication Number Publication Date
MA33607B1 true MA33607B1 (fr) 2012-09-01

Family

ID=43431796

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34720A MA33607B1 (fr) 2009-10-02 2012-03-26 Molécules de liaison bispécifiques pour une thérapie anti-angiogénique

Country Status (24)

Country Link
US (2) US20110172398A1 (fr)
EP (1) EP2483314A1 (fr)
JP (2) JP5833009B2 (fr)
KR (1) KR20120101375A (fr)
CN (2) CN105037542A (fr)
AP (1) AP2012006188A0 (fr)
AR (1) AR078515A1 (fr)
AU (1) AU2010302589A1 (fr)
BR (1) BR112012007239A2 (fr)
CA (1) CA2775422A1 (fr)
CL (1) CL2012000826A1 (fr)
EA (1) EA201200548A1 (fr)
EC (1) ECSP12011835A (fr)
IL (1) IL218542A0 (fr)
IN (1) IN2012DN02752A (fr)
MA (1) MA33607B1 (fr)
MX (1) MX2012003897A (fr)
NZ (2) NZ626302A (fr)
PE (1) PE20121024A1 (fr)
PH (1) PH12012500525A1 (fr)
TN (1) TN2012000145A1 (fr)
TW (1) TW201124533A (fr)
UY (1) UY32920A (fr)
WO (1) WO2011039370A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2066694T3 (en) * 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (fr) 2008-06-03 2009-12-10 Tariq Ghayur Immunoglobulines a deux domaines variables et leurs utilisations
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
WO2010129304A2 (fr) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
BR112012004546A8 (pt) 2009-08-29 2017-12-05 Abbott Lab Terapêutica por proteínas ligantes dll4-ligantes
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
EP2493921B1 (fr) 2009-10-30 2018-09-26 Albumedix Ltd Variants d'albumine
KR101853278B1 (ko) 2010-03-02 2018-05-02 애브비 인코포레이티드 치료학적 ｄｌｌ４ 결합 단백질
EP2566892B1 (fr) 2010-05-06 2017-12-20 Novartis AG Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6)
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
KR20130126576A (ko) 2010-07-19 2013-11-20 에프. 호프만-라 로슈 아게 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
CA2805618A1 (fr) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Methode d'identification d'un patient presentant une probabilite accrue de repondre a un traitement anticancereux
EP3252072A3 (fr) 2010-08-03 2018-03-14 AbbVie Inc. Immunoglobuline à double domaine variable et ses utilisations
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US20130323265A1 (en) * 2010-11-15 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
AU2015268749B2 (en) * 2011-09-23 2017-05-25 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
EP2780364A2 (fr) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
JP2015532272A (ja) * 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
KR20150060686A (ko) * 2012-09-28 2015-06-03 베링거 인겔하임 인터내셔날 게엠베하 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물
EP2906295A4 (fr) * 2012-10-15 2016-06-01 Oncomed Pharm Inc Méthodes de traitement de maladies oculaires
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
CN105431453A (zh) * 2012-11-01 2016-03-23 艾伯维公司 稳定的双重可变结构域免疫球蛋白制剂
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
WO2014144280A2 (fr) 2013-03-15 2014-09-18 Abbvie Inc. Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1β et/ou il -17
ES2742855T3 (es) * 2013-07-09 2020-02-17 Ablbio Nueva proteína de objetivo doble que se une específicamente a DLL4 y CEGF, y uso de la misma
WO2015123359A1 (fr) * 2014-02-11 2015-08-20 Albany Medical College Plate-forme de vaccin mucosal multi-fonctionnel
EP3125937A4 (fr) * 2014-04-04 2017-11-01 Oncomed Pharmaceuticals, Inc. Traitement du cancer gastrique
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016192613A1 (fr) * 2015-06-01 2016-12-08 中山大学 Anticorps bivalent comportant un fragment de liaison à l'antigène à domaine unique fusionné à un fragment fab classique
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
CN109069871A (zh) * 2015-12-04 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的新抗体
JP6879511B2 (ja) * 2016-01-29 2021-06-02 国立大学法人京都大学 血小板産生促進剤及びそれを用いた血小板の製造方法
MX2019008827A (es) * 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
WO2019151865A1 (fr) * 2018-02-05 2019-08-08 Stichting Vu Anticorps anti-us28 agonistes inverses
AU2019232001B2 (en) 2018-03-09 2025-02-20 Valitor, Inc. Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation
CN111995686B (zh) * 2019-05-27 2022-06-14 兰州大学 一种具有抗血管生成活性的药物及其制备方法
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
WO2022057888A1 (fr) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 Molécule de liaison à l'antigène bispécifique se liant spécifiquement au vegf et à l'ang-2
CN112535738B (zh) * 2020-12-04 2022-09-09 中国科学技术大学 奥沙利铂偶联物及其制备方法和应用
KR20230142838A (ko) * 2021-02-10 2023-10-11 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 항-vegf 항체 및 이의 용도
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途
WO2023092327A1 (fr) * 2021-11-24 2023-06-01 Linno Pharmaceuticals Inc. Protéine de liaison au vegf et son utilisation
CN116063469B (zh) * 2022-08-29 2023-09-22 中山大学 一种寨卡病毒中和性纳米抗体及其制备方法与应用
CN119790077A (zh) * 2022-09-14 2025-04-08 寻济生物科技（北京）有限公司 一种抗vegfa融合蛋白及其制备方法和应用
AU2023340044A1 (en) * 2022-09-14 2025-04-03 Quaerite Biopharm Research (Beijing) Co., Ltd. Anti-vegfa antibody or antigen-binding fragment thereof and use thereof
EP4620979A1 (fr) 2022-11-14 2025-09-24 Cognano, Inc. Anticorps et procédé de production d'anticorps
CN117686722B (zh) * 2023-12-20 2024-08-09 内蒙古元牛繁育科技有限公司 一种s100a4纳米抗体及其应用
CN117860786B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途
CN120025456B (zh) * 2024-03-13 2025-11-07 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用
WO2025212751A1 (fr) * 2024-04-02 2025-10-09 Therini Bio, Inc. Protéines de liaison à l'antigène multi-spécifiques se liant au domaine yc de la fibrine humaine ou au domaine yc du fibrinogène et au facteur de croissance endothéliale vasculaire et procédés d'utilisation
US20260092125A1 (en) * 2024-09-06 2026-04-02 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP2213743A1 (fr) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Protéines de fusion d'albumine
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
WO2003059934A2 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Proteines de fusion d'albumine
WO2004041863A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique diriges contre un interferon gamma et leurs utilisations
EP1558645B1 (fr) 2002-11-08 2011-07-27 Ablynx N.V. Anticorps a domaine unique stabilises dans une composition pharmaceutique pour inhalation
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
JP2006517789A (ja) * 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
WO2005040219A1 (fr) * 2003-10-28 2005-05-06 Novo Nordisk A/S Peptides fixant la laminine-5 gamma-2, compositions associees et leurs applications
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) * 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2630839C (fr) 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4
NZ572177A (en) * 2006-06-06 2012-02-24 Genentech Inc Anti-dll4 antibodies and methods using same
ZA200809100B (en) * 2006-06-06 2009-12-30 Genentech Inc Anti-DLL4 antibodies and methods using same
EP2029159A2 (fr) 2006-06-06 2009-03-04 Genentech, Inc. Compositions et procédés destinés à moduler le développement vasculaire
HRP20130271T1 (hr) * 2006-08-07 2013-04-30 Regeneron Pharmaceuticals, Inc. Upotreba dii4 antagonista kod ishemijskih ozljeda ili vaskularne insuficijencije
WO2008020079A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6
US20080132451A1 (en) * 2006-12-01 2008-06-05 Alcon Manufacturing Ltd. Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2121757A2 (fr) * 2007-02-21 2009-11-25 Ablynx N.V. Séquences d'acides aminés dirigées contre le facteur de croissance de l'endothélium vasculaire et polypeptides comprenant ces séquences, pour le traitement de troubles et de maladies se caractérisant par une angiogenèse pathologique ou une néovascularisation
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009095489A2 (fr) 2008-02-01 2009-08-06 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
JP2011516520A (ja) * 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
SG190572A1 (en) * 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010129304A2 (fr) * 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy

Also Published As

Publication number Publication date
JP5833009B2 (ja) 2015-12-16
WO2011039370A1 (fr) 2011-04-07
PH12012500525A1 (en) 2012-11-26
AU2010302589A1 (en) 2012-04-19
CN102639566A (zh) 2012-08-15
BR112012007239A2 (pt) 2019-09-24
EA201200548A1 (ru) 2012-12-28
JP2013506411A (ja) 2013-02-28
MX2012003897A (es) 2012-05-08
EP2483314A1 (fr) 2012-08-08
US20140120095A1 (en) 2014-05-01
CA2775422A1 (fr) 2011-04-07
CN102639566B (zh) 2015-07-22
TN2012000145A1 (en) 2013-09-19
KR20120101375A (ko) 2012-09-13
ECSP12011835A (es) 2012-06-29
TW201124533A (en) 2011-07-16
CN105037542A (zh) 2015-11-11
CL2012000826A1 (es) 2012-10-19
NZ598956A (en) 2014-07-25
AP2012006188A0 (en) 2012-04-30
IL218542A0 (en) 2012-05-31
NZ626302A (en) 2015-09-25
UY32920A (es) 2011-04-29
IN2012DN02752A (fr) 2015-09-18
PE20121024A1 (es) 2012-08-10
US20110172398A1 (en) 2011-07-14
JP2016026207A (ja) 2016-02-12
AR078515A1 (es) 2011-11-16

Similar Documents

Publication Publication Date Title
MA33607B1 (fr) Molécules de liaison bispécifiques pour une thérapie anti-angiogénique
MA33609B1 (fr) Molecules de liaison a dll4
MA34979B1 (fr) Molecules de liaisonbispecifiques se liant a vegf et ang2
MA35233B1 (fr) Molecules de liaison bispecifiques se liant à dii4 et ang2
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
MA44547A1 (fr) Anticorps anti-pd-1,procédé de leur production et de leur utilisation
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA45029A (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA56289A (fr) Mutéines d'interleukine-21 et méthodes de traitement
MX2009002418A (es) Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MX345226B (es) Formulaciones de moleculas de union a antigeno de dominio sencillo.
CA2820681C (fr) Utilisation de lymphocytes t modifies par un recepteur chimerique d'antigenes chimerique pour traiter le cancer
MX350355B (es) Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a.
EA201000910A1 (ru) Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения
EA200900424A1 (ru) Человеческие антитела, которые связываются с cxcr4, и их применение
EA201100239A1 (ru) Композиции, одновалетные в отношении связывания cd28, и способы их применения
MA35437B1 (fr) Proteines de fusion pour le traitement de troubles du metabolisme
MA40249A (fr) Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MA38478A1 (fr) Anticorps anti-pac1 humains
MA39342B2 (fr) Anticorps il -21
JOP20220357A1 (ar) ربط أجسام مضادة متعددة الخصوصية مع bcma
MA44922B1 (fr) Anticorps